부산대학교 도서관

Aim: Stereotactic ablative body radiation (SABRT) for lung cancer is a validated treatment’s option for early stage and advanced or oligoprogression disease. Therapeutic strategy in lung cancer for eldery patients is limited by their comorbidities or perfomance status. This is a retrospective analysis to evaluate the safety and efficiency of SBRT for the treatment of lung lesions in elderly patients. Material and methods: Between April 2018 and January 2021, 44 patients (pts) with more than seventy years old affected by lung cancer in early stage or advanced disease (lung metastasis) were treated with SABRT. Only one or two lesions were irradiated in each patients (total lesions: 60) Median age was 83,5 years (range 70-91). Patients were stratified by stage: stage IV (19), stage I (18), local relapse of previous surgery (7). Lesions’ histology distribution was: adenocarcinoma (26), squamous cell carcinoma (7), small cell lung cancer (5) and unknown (22) - biopsy not possible for medical condition. Lesions were treated with four different fractioned regimens depending on location: 50 Gy /5 fr (19), 45 Gy/ 3 fr (23), 54 Gy/3 fr (8) and 60 Gy/ 8 fr (10), prescribed to 80% median isodose curve (71,8-83%). Local control (LC) was defined by RECIST criteria, overall survival (OS) and toxicity according to CTCAE (v.4) were collected and analyzed retrospectively. Results: Median follow-up was 10 months (2,2-38,2 months). Local control (LC) rate was 85,3% and 74% at 12 and 24 months respectively. Twelve and 24 months - OS was 67,2% and 57,1% respectively. Dividing patients by stage, in stage I 12 and 24 months OS was 64,9% and 32,5%, while in stage IV 57% and 48,9%, with a difference not statistically significantly (p-value: 0,17). Significant lung toxicity wasn’t registered. Only two patients had G1 side effects: one, asthenia and the other thoracic wall pain. Conclusion: Based on our experience, SABR for eldery patients affected by lung cancer is efficient, well tolerated with a good patient’s compliance. In our opinion should be a valid option for the therapeutic strategy for this setting of patients. Further patients need to be treated in order to obtain a confirmation of this promising preliminary result. [ABSTRACT FROM AUTHOR]